FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4309579007> ?p ?o ?g. }

• W4309579007 endingPage "65" @default.
• W4309579007 startingPage "58" @default.
• W4309579007 abstract "To report acute toxicity and health-related quality of life (HRQoL) outcomes of a phase II clinical trial of magnetic resonance imaging (MRI)-guided prostate high-dose-rate brachytherapy (HDR-BT) combined with external beam radiotherapy.Patients with intermediate- and high-risk prostate cancer (PCa) were eligible. Treatment consisted of a single 15 Gy MRI-guided HDR-BT followed by external beam radiotherapy (37.5-46 Gy depending on their risk category). Dosimetry, toxicity and HRQoL outcomes were collected prospectively at baseline, 1 and 3 months using Common Terminology Criteria for Adverse Events Version 4.0 and the expanded PCa index composite, respectively. General linear mixed modeling was conducted to assess the changes in expanded PCa index composite domain scores over time. A minimally important difference was defined as a deterioration of HRQoL scores at 3 months compared to baseline ≥ 0.5 standard deviation. A p value ≤ 0.05 was considered statistically significant.Sixty-one patients were included. Acute grade (G)2 urinary toxicity was observed in 18 (30%) patients while 1 (2%) patient had G3 toxicity, and none had G4 toxicity. Two patients had an acute urinary retention. G2 gastrointestinal toxicity was reported by 5 (8%) patients with no G3-4. Compared to baseline, urinary HRQoL scores significantly declined at 1 month (p < 0.001) but recovered at 3 months (p > 0.05). Bowel (p < 0.001) and sexual (p < 0.001) domain scores showed a significant decline over the 3-month follow-up period. At 3 months, 44%, 49% and 57% of patients reported a minimally important difference respectively in the urinary bowel and sexual domains.MRI-guided HDR-BT boost is a safe and well tolerated treatment of intermediate- and high-risk PCa in the acute setting. A longer follow-up and a comparison to ultrasound-based HDR-BT are needed to assess the potential benefit of MRI-guided prostate HDR-BT." @default.
• W4309579007 created "2022-11-28" @default.
• W4309579007 creator A5004809991 @default.
• W4309579007 creator A5005184189 @default.
• W4309579007 creator A5008579897 @default.
• W4309579007 creator A5009885568 @default.
• W4309579007 creator A5019019620 @default.
• W4309579007 creator A5050365329 @default.
• W4309579007 creator A5052625843 @default.
• W4309579007 creator A5065478544 @default.
• W4309579007 creator A5073843555 @default.
• W4309579007 creator A5076149188 @default.
• W4309579007 creator A5078348186 @default.
• W4309579007 creator A5091336952 @default.
• W4309579007 date "2023-01-01" @default.
• W4309579007 modified "2023-10-07" @default.
• W4309579007 title "Acute toxicity and health-related quality of life outcomes of localized prostate cancer patients treated with magnetic resonance imaging-guided high-dose-rate brachytherapy: A prospective phase II trial" @default.
• W4309579007 cites W1499310009 @default.
• W4309579007 cites W1967144750 @default.
• W4309579007 cites W1977733462 @default.
• W4309579007 cites W1986031929 @default.
• W4309579007 cites W2004201761 @default.
• W4309579007 cites W2015594539 @default.
• W4309579007 cites W2016042230 @default.
• W4309579007 cites W2037565714 @default.
• W4309579007 cites W2040178111 @default.
• W4309579007 cites W2041203398 @default.
• W4309579007 cites W2047912614 @default.
• W4309579007 cites W2049677718 @default.
• W4309579007 cites W2062313368 @default.
• W4309579007 cites W2063839138 @default.
• W4309579007 cites W2073970180 @default.
• W4309579007 cites W2085471307 @default.
• W4309579007 cites W2086604707 @default.
• W4309579007 cites W2095963917 @default.
• W4309579007 cites W2117584600 @default.
• W4309579007 cites W2124681976 @default.
• W4309579007 cites W2125843529 @default.
• W4309579007 cites W2131398800 @default.
• W4309579007 cites W2137282952 @default.
• W4309579007 cites W2150212745 @default.
• W4309579007 cites W2163954169 @default.
• W4309579007 cites W2165244734 @default.
• W4309579007 cites W2290034687 @default.
• W4309579007 cites W2553678345 @default.
• W4309579007 cites W2569728867 @default.
• W4309579007 cites W2586272675 @default.
• W4309579007 cites W2716892249 @default.
• W4309579007 cites W2768304884 @default.
• W4309579007 cites W2945855863 @default.
• W4309579007 cites W4225137874 @default.
• W4309579007 cites W4249322584 @default.
• W4309579007 doi "https://doi.org/10.1016/j.brachy.2022.08.015" @default.
• W4309579007 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36414526" @default.
• W4309579007 hasPublicationYear "2023" @default.
• W4309579007 type Work @default.
• W4309579007 citedByCount "1" @default.
• W4309579007 countsByYear W43095790072023 @default.
• W4309579007 crossrefType "journal-article" @default.
• W4309579007 hasAuthorship W4309579007A5004809991 @default.
• W4309579007 hasAuthorship W4309579007A5005184189 @default.
• W4309579007 hasAuthorship W4309579007A5008579897 @default.
• W4309579007 hasAuthorship W4309579007A5009885568 @default.
• W4309579007 hasAuthorship W4309579007A5019019620 @default.
• W4309579007 hasAuthorship W4309579007A5050365329 @default.
• W4309579007 hasAuthorship W4309579007A5052625843 @default.
• W4309579007 hasAuthorship W4309579007A5065478544 @default.
• W4309579007 hasAuthorship W4309579007A5073843555 @default.
• W4309579007 hasAuthorship W4309579007A5076149188 @default.
• W4309579007 hasAuthorship W4309579007A5078348186 @default.
• W4309579007 hasAuthorship W4309579007A5091336952 @default.
• W4309579007 hasConcept C116263406 @default.
• W4309579007 hasConcept C121608353 @default.
• W4309579007 hasConcept C126322002 @default.
• W4309579007 hasConcept C126838900 @default.
• W4309579007 hasConcept C126894567 @default.
• W4309579007 hasConcept C143409427 @default.
• W4309579007 hasConcept C159110408 @default.
• W4309579007 hasConcept C188816634 @default.
• W4309579007 hasConcept C197934379 @default.
• W4309579007 hasConcept C2775908122 @default.
• W4309579007 hasConcept C2777416452 @default.
• W4309579007 hasConcept C2777793932 @default.
• W4309579007 hasConcept C2779951463 @default.
• W4309579007 hasConcept C2780192828 @default.
• W4309579007 hasConcept C29730261 @default.
• W4309579007 hasConcept C509974204 @default.
• W4309579007 hasConcept C71924100 @default.
• W4309579007 hasConcept C77411442 @default.
• W4309579007 hasConceptScore W4309579007C116263406 @default.
• W4309579007 hasConceptScore W4309579007C121608353 @default.
• W4309579007 hasConceptScore W4309579007C126322002 @default.
• W4309579007 hasConceptScore W4309579007C126838900 @default.
• W4309579007 hasConceptScore W4309579007C126894567 @default.
• W4309579007 hasConceptScore W4309579007C143409427 @default.
• W4309579007 hasConceptScore W4309579007C159110408 @default.
• W4309579007 hasConceptScore W4309579007C188816634 @default.
• W4309579007 hasConceptScore W4309579007C197934379 @default.

• next